Levetiracetam Solution
Product Images NDC 39328-511

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 39328-511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Patrin Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 01)

FDA Label Image

Figure 1 (Levetiracetam 02)

This text provides statistical data on the percentage of patients for Placebo and different doses of Levetiracetam (1000 mg/day and 3000 mg/day). It indicates that the results for Levetiracetam at 3000 mg/day are statistically significant compared to the placebo.*

FDA Label Image

Figure 2 (Levetiracetam 03)

This is a statistical table presenting percentages for different treatment groups. It compares the effectiveness of placebo, and two different doses of Levetiracetam (1000 mg/day and 2000 mg/day). The table indicates that there are statistically significant differences in effectiveness between the Levetiracetam groups and the placebo group.*

FDA Label Image

Figure 3 (Levetiracetam 04)

This text shows percentage values and statistics for a comparison between a placebo group (N=104) and a group taking 3000 mg/day of Levetiracetam (N=180). The data indicates a statistically significant difference between the two groups.*

FDA Label Image

Figure 4 (Levetiracetam 05)

This text provides a comparison of the percentages of patients in two groups - Placebo (N=97) and Levetiracotam (N=101). It indicates that there is a statistically significant difference between the two groups.*

FDA Label Image

Figure 5 (Levetiracetam 06)

This text provides percentages for two different groups (19.6% and 43.1%) and mentions that one group is statistically significant versus the placebo group. It also indicates the sample sizes for the placebo group (N=51) and levetiracetam group (N=58). The information seems to be related to a study or clinical trial comparing the effects of levetiracetam with a placebo.*

FDA Label Image

Figure 6 (Levetiracetam 07)

This text appears to be a representation of a clinical trial result table comparing the effects of a placebo (with 84 patients) and Levetiracetam (with 79 patients) on patients. The percentages likely indicate the effectiveness or outcomes for different groups, with a note mentioning statistical significance versus the placebo group. The specific results or measurements are not provided.*

FDA Label Image

Principal Display Panel (5 mL Cup Label)

This text contains information about a medication: - Brand: Rx Ong, - Product: Levetiracetam - Form: Oral Solution, USP - Strength: 500 mg/5 mL - For institutional use only - NDC: 33325-511-05 - Manufacturer: Patrin Pharma - Expiry Date: YYYY/MM/DD This medication is an oral solution of Levetiracetam with a concentration of 500 mg per 5 mL. It is intended for institutional use only and is manufactured by Patrin Pharma.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.